CagriSema: Novo Nordisk's 22.7% Weight Loss Drug Explained
CagriSema is Novo Nordisk's most ambitious new obesity drug. It combines two separate hormone targeting mechanisms in a single weekly injection and Phase 3 data shows it significan...
Tag archive
Browse every WeightEasy article tagged New Drug.
Use tag archives to move laterally through related articles. This is useful when you want narrower guidance than a broad category page, such as reviewing articles about a specific medication, symptom, or routine concept.
CagriSema is Novo Nordisk's most ambitious new obesity drug. It combines two separate hormone targeting mechanisms in a single weekly injection and Phase 3 data shows it significan...
Orforglipron is the most anticipated new GLP 1 drug of 2026. Developed by Eli Lilly, it is a once daily oral pill with no injection and no fasting requirements a combination that d...
Retatrutide is the drug that may redefine how the medical world thinks about weight loss. In one Phase 3 clinical trial, participants lost an average of 71.2 lbs (32.3 kg) over 68...